Lungs News and Research

RSS

UC Davis research highlights need for better guidance for primary care providers

Short questionnaires used to identify patients at risk for depression are linked with antidepressant medications being prescribed when they may not be needed, according to new research from UC Davis Health System published in the September-October issue of the Journal of the American Board of Family Medicine.

30 Sep 2014

New scaling law helps predict humans' risk of blast-induced traumatic brain injury

Since the start of the military conflicts in Iraq and Afghanistan, more than 300,000 soldiers have returned to the United States with traumatic brain injury caused by exposure to bomb blasts - and in particular, exposure to improvised explosive devices, or IEDs. Symptoms of traumatic brain injury can range from the mild, such as lingering headaches and nausea, to more severe impairments in memory and cognition.

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

CFDA clears Elekta's Versa HD radiation therapy system

Following US and European approvals of Elekta's Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country.

From Elekta 30 Sep 2014

New OSU study shows association between gas kitchen stove ventilation and asthma

Parents with children at home should use ventilation when cooking with a gas stove, researchers from Oregon State University are recommending, after a new study showed an association between gas kitchen stove ventilation and asthma, asthma symptoms and chronic bronchitis.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center.

29 Sep 2014

Study provides support for new understanding of the immune system

A study published in the journal Science provides support for a new-and still controversial-understanding of the immune system. The research was conducted by collaborators in the U.S. and Europe, including Robert Cramer, PhD, an assistant professor of microbiology and immunology at the Geisel School of Medicine and member of the Dartmouth Lung Biology Center, and Kelly Shepherdson, PhD, at the time a graduate student in Cramer's lab.

29 Sep 2014

Leading Cystic Fibrosis experts call for greater research on antibacterial resistance

World leading Cystic Fibrosis experts, from Queen's University Belfast, have called for greater research to address the major concern of antibacterial resistance.

29 Sep 2014

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

US children with cystic fibrosis have better lung function compared to UK counterparts

There are significant differences in the lung function of children and young adults in the United States (US) who have cystic fibrosis compared with those in the United Kingdom (UK).

27 Sep 2014

Study: Simple blood test could identify people with hypercalcaemia

High levels of calcium in blood, a condition known as hypercalcaemia, can be used by GPs as an early indication of certain types of cancer, according to a study by researchers from the universities of Bristol and Exeter.

26 Sep 2014

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

Lungs News and Research

UC Davis research highlights need for better guidance for primary care providers

New scaling law helps predict humans' risk of blast-induced traumatic brain injury

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

CFDA clears Elekta's Versa HD radiation therapy system

New OSU study shows association between gas kitchen stove ventilation and asthma

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Targeted treatments may improve idiopathic PAH survival

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Researchers create new Cas9 animal model for in vivo genome editing experiments

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Study provides support for new understanding of the immune system

Leading Cystic Fibrosis experts call for greater research on antibacterial resistance

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

US children with cystic fibrosis have better lung function compared to UK counterparts

Study: Simple blood test could identify people with hypercalcaemia

Study findings have potential to advance treatments for small cell lung cell cancer

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News